Dyne Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
DYN$18.62+3.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share data)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $753,102 | $893,369 |
| Marketable securities | 219,054 | 217,193 |
| Prepaid expenses and other current assets | 48,871 | 16,025 |
| Total current assets | 1,021,027 | 1,126,587 |
| Property and equipment, net | 23,682 | 24,029 |
| Right-of-use assets | 19,652 | 20,742 |
| Restricted cash and other assets | 15,589 | 15,600 |
| Total assets | $1,079,950 | $1,186,958 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | 10,781 | 8,082 |
| Accrued expenses and other current liabilities | 29,211 | 37,548 |
| Vendor financing arrangement | 6,224 | — |
| Lease liabilities | 5,033 | 4,995 |
| Total current liabilities | 51,249 | 50,625 |
| Long-term debt, net | 149,375 | 148,921 |
| Lease liabilities, net of current portion | 14,271 | 15,283 |
| Total liabilities | 214,895 | 214,829 |
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; 165,201,329 and 164,950,540 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 16 | 16 |
| Additional paid-in capital | 2,382,172 | 2,367,780 |
| Accumulated other comprehensive loss (gain) | (137) | 475 |
| Accumulated deficit | (1,516,996) | (1,396,142) |
| Total stockholders’ equity | 865,055 | 972,129 |
| Total liabilities and stockholders’ equity | $1,079,950 | $1,186,958 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.